TY - JOUR
T1 - Naturally occurring 2′-hydroxyl-substituted flavonoids as high-affinity benzodiazepine site ligands
AU - Huen, Michael S.Y.
AU - Hui, Kwok Min
AU - Leung, Justin W.C.
AU - Sigel, Erwin
AU - Baur, Roland
AU - Wong, J. Tze Fei
AU - Xue, Hong
PY - 2003/12/15
Y1 - 2003/12/15
N2 - Screening of traditional medicines has proven invaluable to drug development and discovery. Utilizing activity-guided purification, we previously reported the isolation of a list of flavonoids from the medicinal herb Scutellaria baicalensis Georgi, one of which manifested an affinity for the benzodiazepine receptor (BDZR) comparable to that of the synthetic anxiolytic diazepam (Ki=6.4nM). In the present study, this high-affinity, naturally occurring flavonoid derivative, 5,7,2′- trihydroxy-6,8-dimethoxyflavone (K36), was chosen for further functional and behavioral characterization. K36 inhibited [3H]flunitrazepam binding to native BDZR with a Ki value of 6.05nM. In electrophysiological experiments K36 potentiated currents mediated by rat recombinant α 1β2γ2 GABAA receptors expressed in Xenopus oocytes. This potentiation was characterized by a threshold (1nM) and half-maximal stimulation (24nM) similar to diazepam. This enhancement was demonstrated to act via the BDZR, since co-application of 1μM of the BDZR antagonist Ro15-1788 reversed the potentiation. Oral administration of K36 produced significant BDZR-mediated anxiolysis in the mice elevated plus-maze, which was abolished upon co-administration of Ro15-1788. Sedation, myorelaxation and motor incoordination were not observed in the chosen dosage regimen. Structure-activity relationships utilizing synthetic flavonoids with different 2′ substituents on the flavone backbone supported that 2′-hydroxyl-substitution is a critical moiety on flavonoids with regard to BDZR affinities. These results further underlined the potential of flavonoids as therapeutics for the treatment of BDZR-associated syndromes.
AB - Screening of traditional medicines has proven invaluable to drug development and discovery. Utilizing activity-guided purification, we previously reported the isolation of a list of flavonoids from the medicinal herb Scutellaria baicalensis Georgi, one of which manifested an affinity for the benzodiazepine receptor (BDZR) comparable to that of the synthetic anxiolytic diazepam (Ki=6.4nM). In the present study, this high-affinity, naturally occurring flavonoid derivative, 5,7,2′- trihydroxy-6,8-dimethoxyflavone (K36), was chosen for further functional and behavioral characterization. K36 inhibited [3H]flunitrazepam binding to native BDZR with a Ki value of 6.05nM. In electrophysiological experiments K36 potentiated currents mediated by rat recombinant α 1β2γ2 GABAA receptors expressed in Xenopus oocytes. This potentiation was characterized by a threshold (1nM) and half-maximal stimulation (24nM) similar to diazepam. This enhancement was demonstrated to act via the BDZR, since co-application of 1μM of the BDZR antagonist Ro15-1788 reversed the potentiation. Oral administration of K36 produced significant BDZR-mediated anxiolysis in the mice elevated plus-maze, which was abolished upon co-administration of Ro15-1788. Sedation, myorelaxation and motor incoordination were not observed in the chosen dosage regimen. Structure-activity relationships utilizing synthetic flavonoids with different 2′ substituents on the flavone backbone supported that 2′-hydroxyl-substitution is a critical moiety on flavonoids with regard to BDZR affinities. These results further underlined the potential of flavonoids as therapeutics for the treatment of BDZR-associated syndromes.
KW - Anxiolytics
KW - Benzodiazepine receptor
KW - Benzodiazepines
KW - Flavonoids
KW - Scutellaria baicalensis Georgi
KW - Structure-activity relationship
UR - http://www.scopus.com/inward/record.url?scp=0344154296&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0344154296&partnerID=8YFLogxK
U2 - 10.1016/j.bcp.2003.08.016
DO - 10.1016/j.bcp.2003.08.016
M3 - Article
C2 - 14637197
AN - SCOPUS:0344154296
SN - 0006-2952
VL - 66
SP - 2397
EP - 2407
JO - Biochemical Pharmacology
JF - Biochemical Pharmacology
IS - 12
ER -